-

Arrivo Bio to Present and Meet with Investors at the 37th Annual Piper Sandler Healthcare Conference

MORRISVILLE, N.C.--(BUSINESS WIRE)--Arrivo Bio today announced that members of its executive management team will participate in the 37th Annual Piper Sandler Healthcare Conference, being held on December 2–4 in New York, New York. The team will host investor meetings and present an overview of the Company’s business and pipeline.

Presentation Details:

  • Date: Thursday, December 4, 2025
  • Time: 1:30-1:50pm ET
  • Participants: Steve Butts, Co-founder and Chief Executive Officer, and Greg Rigdon PhD, Senior Vice President of Scientific Affairs

About Arrivo Bio
Arrivo is developing first-of-its-kind medicines that target the root cause of hard-to-treat diseases with the goal of achieving meaningful outcomes for patients, allowing them to live longer, healthier lives. Arrivo has two clinical-stage pipeline candidates, Forvisirvat (SP-624) for major depressive disorder and RABI-767 for predicted severe acute pancreatitis. Arrivo is based in Morrisville, N.C., on the edge of Research Triangle Park. For more information, visit www.arrivobio.com.

Contacts

Media:
Alexis Feinberg
Alexis.Feinberg@icrhealthcare.com

Investor:
Aman R. Patel, CFA & Adanna G. Alexander, PhD
Aman.Patel@icrhealthcare.com & Adannna.Alexander@icrhealthcare.com

Industry:

Arrivo Bio

Release Versions
English

Contacts

Media:
Alexis Feinberg
Alexis.Feinberg@icrhealthcare.com

Investor:
Aman R. Patel, CFA & Adanna G. Alexander, PhD
Aman.Patel@icrhealthcare.com & Adannna.Alexander@icrhealthcare.com

More News From Arrivo Bio

Arrivo BioVentures Announces Positive Results from qEEG and BNA™ Study of SP-624 on Neural Brain Activity Related to Depression and Cognition

MORRISVILLE, N.C.--(BUSINESS WIRE)--Arrivo BioVentures today announced positive data from its SP-624-103 study evaluating the impact of SP-624’s novel epigenetic mechanism of action on neurological pathways. The findings provide insights into the potential antidepressant and cognitive effects of SP-624, a SIRT6 activator that may be the first treatment specifically for females with Major Depression based on previous studies. Arrivo’s SP-624-103 study is a double blind, placebo-controlled study...

Arrivo BioVentures Begins Phase 1 Study of SP-624, the First Potential Treatment Specifically for Women with Major Depressive Disorder

MORRISVILLE, N.C.--(BUSINESS WIRE)--Arrivo BioVentures announced today that it has enrolled the first subject in a Phase 1 exploratory study of the company’s first-in-class SIRT6 activator, SP-624, in healthy volunteers and patients with major depressive disorder (MDD). The study is designed to evaluate the impact of the epigenetic mechanism of action of SP-624, on neurological pathways and assess changes in various cognitive domains. SP-624 is also currently being studied in a large Phase 2b s...
Back to Newsroom